Canada Markets open in 8 hrs 55 mins

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.6200+0.0700 (+1.54%)
At close: 04:00PM EST
4.6200 0.00 (0.00%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close4.5500
Open4.5500
Bid0.0000 x 800
Ask0.0000 x 1800
Day's Range4.4800 - 4.7000
52 Week Range4.0300 - 11.2400
Volume132,312
Avg. Volume312,293
Market Cap216.753M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-2.1850
Earnings DateFeb. 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct. 31, 2014
1y Target Est21.75
  • GlobeNewswire

    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on November 30, 2021, the Company granted stock options to ten new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, I

  • GlobeNewswire

    Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

    BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The on-demand presentation will be available Thursday, Nov. 18 beginning at 3 a.m. EST through Friday, Nov. 19 at 12 p.m. EST. To access the webcast, please visit: https://wsw.meetmax.com/admin/presenterlinks/?436013913&group=TbkBHEif. A replay of the webcast can be accessed for up to 30 day

  • Zacks

    Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates

    Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?